{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T05:20:46Z","timestamp":1774416046548,"version":"3.50.1"},"reference-count":20,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2026,2,22]],"date-time":"2026-02-22T00:00:00Z","timestamp":1771718400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2026,2,22]],"date-time":"2026-02-22T00:00:00Z","timestamp":1771718400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Fundamemntal Clinical Pharma"],"published-print":{"date-parts":[[2026,3]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Sodium glucose co\u2010transporter type 2 inhibitors (SGLT2i) were initially developed as glucose\u2010lowering drugs for diabetic patients. A few years after their market authorization in Europe, their indications were expanded to include first, heart failure (HF) and, subsequently, chronic kidney disease (CKD). These expansions led to a rapid increase in the use of this drug class and a diversification of the treated patient profile in the \u201creal\u2010life.\u201d<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Describe in\u2010hospital SGLT2i user profiles and evaluate compliance with guidelines.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A descriptive cross\u2010sectional study was conducted using the Bordeaux University Hospital's clinical data warehouse. It included a random sample of 250 hospital stays of different patients with at least one administration of SGLT2i between February 1, 2022, and January 31, 2023. SGLT2i user profiles were described in terms of indications. Drug co\u2010prescriptions were also described to evaluate compliance with guidelines.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The majority of patients were aged 60\u201379 (59.6%), and were men (75.2%). HF was found in 87.2% of the patients treated with SGLT2i, followed by T2DM (45.2%) and CKD (21.2%). The most frequent indication profiles were HF without type II diabetes or CKD (42.0%) followed by HF and diabetes without CKD (26.0%). No patient had CKD as the sole indication. Prescriptions were considered compliant with guidelines for 76.4% of patients. Suboptimal prescriptions were mainly due to absence of another recommended drug without justification.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>SGLT2i are now primarily used to treat HF. Their therapeutic potential in CKD appears to be still underestimated. Overall, compliance with guidelines appears satisfactory.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/fcp.70076","type":"journal-article","created":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T05:00:01Z","timestamp":1771822801000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["SGLT\u20102 Inhibitors Use in Hospitalized Patients in France: A Cross\u2010Sectional Study"],"prefix":"10.1111","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-6156-2976","authenticated-orcid":false,"given":"Maxime","family":"Demourgues","sequence":"first","affiliation":[{"name":"Inserm U1219, Bordeaux Population Health Research Center, Team AHeaD, Department of Medical Pharmacology, CHU de Bordeaux University of Bordeaux  Bordeaux France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julien","family":"Bezin","sequence":"additional","affiliation":[{"name":"Inserm U1219, Bordeaux Population Health Research Center, Team AHeaD, Department of Medical Pharmacology, CHU de Bordeaux University of Bordeaux  Bordeaux France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Romain","family":"Griffier","sequence":"additional","affiliation":[{"name":"CHU de Bordeaux, P\u00f4le de Sant\u00e9 Publique, Service d'information M\u00e9dicale, Informatique et Archivistique M\u00e9dicales (IAM)  Bordeaux France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antoine","family":"Pariente","sequence":"additional","affiliation":[{"name":"Inserm U1219, Bordeaux Population Health Research Center, Team AHeaD, Department of Medical Pharmacology, CHU de Bordeaux University of Bordeaux  Bordeaux France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pernelle","family":"Noize","sequence":"additional","affiliation":[{"name":"Inserm U1219, Bordeaux Population Health Research Center, Team AHeaD, Department of Medical Pharmacology, CHU de Bordeaux University of Bordeaux  Bordeaux France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sibylle","family":"de Germay","sequence":"additional","affiliation":[{"name":"Inserm U1219, Bordeaux Population Health Research Center, Team AHeaD, Department of Medical Pharmacology, CHU de Bordeaux University of Bordeaux  Bordeaux France"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2026,2,22]]},"reference":[{"key":"e_1_2_13_2_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc21-1815"},{"key":"e_1_2_13_3_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamacardio.2022.3839"},{"key":"e_1_2_13_4_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12875-022-01731-w"},{"key":"e_1_2_13_5_1","doi-asserted-by":"publisher","DOI":"10.24926\/iip.v14i2.5456"},{"key":"e_1_2_13_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/ehf2.15049"},{"key":"e_1_2_13_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.15623"},{"key":"e_1_2_13_8_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehab368"},{"key":"e_1_2_13_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1523-1755.2005.00365.x"},{"key":"e_1_2_13_10_1","doi-asserted-by":"publisher","DOI":"10.2337\/cd21-as01"},{"issue":"8","key":"e_1_2_13_11_1","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/j.mmm.2021.10.014","article-title":"Prise de Position de la Soci\u00e9t\u00e9 Francophone du Diab\u00e8te (SFD) Sur Les Strat\u00e9gies d'Utilisation des Traitements Anti\u2010Hyperglyc\u00e9miants Dans le Diab\u00e8te de Type 2\u20132021","volume":"15","author":"Darmon P.","year":"2021","journal-title":"M\u00e9decine Mal M\u00e9taboliques"},{"key":"e_1_2_13_12_1","unstructured":"\u201cSummary of Product Characteristics Dapagliflozin Forxiga [Internet] \u201d [cit\u00e9 29 juin 2023] https:\/\/www.ema.europa.eu\/en\/documents\/product\u2010information\/forxiga\u2010epar\u2010product\u2010information_en.pdf."},{"key":"e_1_2_13_13_1","unstructured":"Haute Autorit\u00e9 de Sant\u00e9 \u201cTransparency Committee Summary. Dapagliflozin Forxiga New Indication. 27 October 2021 \u201d [Internet] [cit\u00e9 11 oct 2023] https:\/\/www.has\u2010sante.fr\/upload\/docs\/application\/pdf\/2022\u201003\/forxiga_271021_summary_ct19370.pdf."},{"issue":"10","key":"e_1_2_13_14_1","first-page":"811","article-title":"Effect of Dapagliflozin in Patients With HFrEF Treated With Sacubitril\/Valsartan: The DAPA\u2010HF Trial","volume":"8","author":"Solomon S. D.","year":"2020","journal-title":"Heart Failure"},{"key":"e_1_2_13_15_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.122.010080"},{"key":"e_1_2_13_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14947"},{"key":"e_1_2_13_17_1","unstructured":"Soci\u00e9t\u00e9 Francophone de N\u00e9phrologie Dialyse et Transplantation (SFNDT) \u201cMa Maladie R\u00e9nale Chronique 2022 \u201d (2022)."},{"key":"e_1_2_13_18_1","unstructured":"Ameli Data Pathologies \u201cDiab\u00e8te [Internet] \u201d [cit\u00e9 23 mai 2023] https:\/\/data.ameli.fr\/pages\/pathologies\/?refine.patho_niv1=Diab%C3%A8te."},{"key":"e_1_2_13_19_1","unstructured":"Ameli Data Pathologies \u201cInsuffisance Cardiaque Chronique [Internet] \u201d [cit\u00e9 23 mai 2023] https:\/\/data.ameli.fr\/pages\/pathologies\/?refine.patho_niv1=Maladies%20cardio\u2010neurovasculaires&refine.patho_niv2=Insuffisance%20cardiaque&refine.patho_niv3=Insuffisance%20cardiaque%20chronique."},{"key":"e_1_2_13_20_1","doi-asserted-by":"publisher","DOI":"10.34067\/KID.0007862021"},{"key":"e_1_2_13_21_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehad195"}],"container-title":["Fundamental &amp; Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/fcp.70076","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/fcp.70076","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/fcp.70076","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T04:33:15Z","timestamp":1774413195000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/fcp.70076"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,22]]},"references-count":20,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["10.1111\/fcp.70076"],"URL":"https:\/\/doi.org\/10.1111\/fcp.70076","archive":["Portico"],"relation":{},"ISSN":["0767-3981","1472-8206"],"issn-type":[{"value":"0767-3981","type":"print"},{"value":"1472-8206","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,22]]},"assertion":[{"value":"2025-04-16","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-17","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-22","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70076"}}